ArticleInternational journal of cardiology. Heart & vasculature2025
Prognostic value of TIMI risk score combined with systemic immune-inflammation index and lipoprotein(a) in patients with ST-Segment elevation myocardial infarction after percutaneous coronary intervention.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel Mortality Index Unveils Smoking's Role in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.Acta Cardiologica Sinica · 2026Article
- Comparison of the prognostic value of complete blood count-derived inflammatory markers for long-term outcomes in ST-segment elevation myocardial infarction.Internal and emergency medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombolysis in Myocardial Infarction (TIMI) risk score in patients with ST-segment elevation myocardial infarction (STEMI) is associated with major adverse cardiovascular events (MACE). This study aimed to develop a prediction model based on the TIMI risk score for MACE in STEMI patients after percutaneous coronary intervention (PCI). Methods: We conducted a retrospective data analysis on 290 acute STEMI patients admitted to the Affiliated Hospital of Yangzhou University from January 2022 to June 2023 and met the inclusion criteria. The primary endpoint was the occurrence of MACE. Multivariate logistic regression was used to identify independent predictors that could predict the likelihood of MACE, and R software was utilized to construct and validate the prediction model. Results: Systemic immune-inflammation index (SII), lipoprotein(a) [Lp(a)], and TIMI risk score were identified as independent risk factors for MACE in STEMI patients (p < 0.05). A nomogram was constructed based on these factors. The area under the receiver operating characteristic curve values for the training and validation sets were 0.883 (95 % CI: 0.836-0.930) and 0.841 (95 % CI: 0.756-0.925), respectively. The calibration curves displayed a high consistency between prediction and observation in the training and validation sets. Additionally, decision curve analysis (DCA) demonstrated the clinical usefulness of the nomogram. Conclusions: SII, Lp(a), and TIMI risk score are independent risk factors for MACE within one year in STEMI patients after PCI. Incorporating SII and Lp(a) into the TIMI risk score enhances the predictive value for adverse outcomes, thereby supporting healthcare professionals in clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.